<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110445</url>
  </required_header>
  <id_info>
    <org_study_id>EKNZ 2015-026</org_study_id>
    <nct_id>NCT03110445</nct_id>
  </id_info>
  <brief_title>Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus</brief_title>
  <acronym>rVV-740CTA</acronym>
  <official_title>Monocentric Open Label Phase I Immunotherapy Trial of Breast Cancer Patients With a Non-replicating Recombinant Vaccinia Virus Expressing Cancer/Testis Antigens and Cluster of Differentiation Antigen 80 (CD80)-CD40L Costimulatory Molecules.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monocentric open-label phase I/II trial aiming at evaluating, in adjuvant setting, safety
      (primary outcome), immunological and clinical efficacy (secondary outcomes) of a non
      replicating recombinant vaccinia virus expressing cancer/testis antigen (CTA) derived
      epitopes and CD80 and CD40 ligand (CD40L, CD154) costimulatory molecules in patients with CTA
      expressing tumors.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Safety measured by assessment of number of adverse events that have occured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of serious adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Safety measured by assessment of number of serious adverse Events that have occured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of Immune reactivity to the CTA</measure>
    <time_frame>18 months</time_frame>
    <description>Vaccine epitopes specific CD8+ T-cell responses will be evaluated from peripheral blood samples prior, during and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
    <description>number of patients with no relapse of disease at timepoint 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>number of patients still living at timepoint 2 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>rVV-740CTA vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rVV-740CTA</intervention_name>
    <description>non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)</description>
    <arm_group_label>rVV-740CTA vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Surgically treated M0 patients with solid tumors

          -  Tumor expressing at least one of the vaccine targeted antigens Melanoma-associated
             antigen (MAGE)-A1, -A2,

          -  A3, -A4, -A6, -A10, -A12 or New York (NY) esophageal squamous cell carcinoma-1 (ESO-1)
             (NY-ESO-1) (by real-time quantitative PCR (RT-qPCR))

          -  Patient expressing the targeted Human Leukocyte Antigen (HLA) restriction (A0201
             /A0101/ B3501)

          -  4 weeks interval following surgical resection of tumor and, if applicable, completion
             of adjuvant therapy.

          -  Karnofsky over 70%

          -  No other concomitant malignancy

        Exclusion Criteria:

          -  History of anaphylaxis or severe allergic reaction

          -  Severe heart, lung, kidney, liver or psychiatric condition

          -  Concurrent immunosuppressive therapy or impaired immune system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul ZAJAC, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Basel - Dept of Biomedicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter WEBER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Basel - Dept of Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walter WEBER, MD</last_name>
    <phone>+41. 61 265 2525</phone>
    <email>walter.weber@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Savas SOYSAL, MD</last_name>
    <phone>+41. 61 265 2525</phone>
    <email>savas.soysal@usb.ch</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Vaccinia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>publication per reviewed journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

